🟢 10x Genomics is trading 4.6% up in pre-market after Canaccord and Piper Sandler raised targets

10x Genomics is trading 4.6% up at $61.15 after analysts raised their price targets following the company’s second-quarter results.

• Canaccord raised its target to $60 from $50.
• Piper Sandler increased its target to $47 from $42.
• The upgrades followed stronger-than-expected second-quarter revenue and encouraging Atera demand, while the stock’s recent rally and broader technology-market strength may also be supporting pre-market activity.